Manfred Schmitt

Prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in completely resected gastric cancer.

K. Becker, H. Nekarda, J. Siewert, 1994, Cancer research.

A ligand-free, soluble urokinase receptor is present in the ascitic fluid from patients with ovarian cancer.

F. Jänicke, M. Schmitt, W. Kuhn, 1993, The Journal of clinical investigation.

Urokinase (uPA) and PAI-1 predict survival in advanced ovarian cancer patients (FIGO III) after radical surgery and platinum-based chemotherapy.

P. Dettmar, F. Jänicke, M. Schmitt, 1994, Gynecologic oncology.

Risk-group discrimination in node-negative breast cancer using invasion and proliferation markers: 6-year median follow-up

H. Höfler, N. Harbeck, P. Dettmar, 1999, British Journal of Cancer.

Primary tumor and metastasis in ovarian cancer differ in their content of urokinase-type plasminogen activator, its receptor, and inhibitors types 1 and 2.

H. Höfler, P. Dettmar, F. Jänicke, 1995, Cancer research.

Prognostic significance of urokinase (uPA) and its inhibitor PAI-1 for survival in advanced ovarian carcinoma stage FIGO IIIc

H. Höfler, N. Harbeck, P. Dettmar, 1999, British Journal of Cancer.